{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:01:21Z","timestamp":1773687681189,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.vaccine.2011.05.054","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T05:30:43Z","timestamp":1307943043000},"page":"5107-5113","source":"Crossref","is-referenced-by-count":45,"title":["Trivalent influenza vaccine and febrile adverse events in Australia, 2010: Clinical features and potential mechanisms"],"prefix":"10.1016","volume":"29","author":[{"given":"C.C.","family":"Blyth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.P.","family":"Wiertsema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.S.","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fuery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mascaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.C.","family":"Geelhoed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.05.054_bib0005","unstructured":"Dawood FS, Fiore A, Kamimoto L, Bramley A, Reingold A, Gershman K, et al. Burden of Seasonal Influenza Hospitalization in Children, United States, 2003 to 2008. J Pediatr 2010; published online June 24 2010 (doi: S0022-3476(10)00408-7 [pii]10.1016\/j.jpeds.2010.05.012)."},{"key":"10.1016\/j.vaccine.2011.05.054_bib0010","series-title":"Red Book\u00ae","author":"American Academy of Pediatrics","year":"2010"},{"key":"10.1016\/j.vaccine.2011.05.054_bib0015","unstructured":"Public Health Agency of Canadia. Canadian Immunization Guide, Seventh Edition. Ottawa: Public Works and Government Services Canada; 2006. [cited 28th August 2010: Available from: http:\/\/www.phac-aspc.gc.ca\/im\/is-cv\/#a]."},{"key":"10.1016\/j.vaccine.2011.05.054_bib0020","doi-asserted-by":"crossref","unstructured":"Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 296 (16) 1990-7.","DOI":"10.1001\/jama.296.16.1990"},{"issue":"11","key":"10.1016\/j.vaccine.2011.05.054_bib0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archpedi.158.11.1031","article-title":"Safety of the trivalent inactivated influenza vaccine among children: a population-based study","volume":"158","author":"France","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"10.1016\/j.vaccine.2011.05.054_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1750-2659.2010.00141.x","article-title":"Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine against laboratory-confirmed influenza in hospitalised children aged 6-59 months","volume":"4","author":"Dixon","year":"2010","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2011.05.054_bib0035","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season. Influenza 2010 [cited 28th August 2010; Available from: http:\/\/www.who.int\/csr\/disease\/influenza\/recommendations2010south\/en\/index.html]."},{"key":"10.1016\/j.vaccine.2011.05.054_bib0040","unstructured":"Department of Health and Aging: Therapeutic Goods Administration. Investigation into Febrile Events in Young Children Following 2010 Seasonal Trivalent Influenza Vaccination: Status Report as at 2nd July 2010. Government of Australia, Canberra; 2010. [cited 28th August 2010; Available from http:\/\/www.tga.gov.au\/alerts\/medicines\/fluvaccine-report100702.htm]."},{"key":"10.1016\/j.vaccine.2011.05.054_bib0045","series-title":"International Statistical Classification of Diseases and Related Problems","author":"National Centre for Classification of Health","year":"2004"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2011.05.054_bib0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.vaccine.2003.09.008","article-title":"Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2011.05.054_bib0055","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2009.05.023","article-title":"Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age","volume":"27","author":"Rosenberg","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2011.05.054_bib0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.2004-1519","article-title":"Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990\u20132003","volume":"115","author":"McMahon","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2011.05.054_bib0065","unstructured":"Department of Health and Aging: Australian Technical Advisory Group on Immunisation (ATAGI) Statement. Clinical advice for immunisation providers on resumption of the use of 2010 trivalent seasonal vaccines in children less than 5 years of age. July 2010. Government of Australia, Canberra; 2010. [cited 6th December 2010; Available from http:\/\/www.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/immunise-atagi-statement-tiv]."},{"issue":"1","key":"10.1016\/j.vaccine.2011.05.054_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/cimm.1998.1295","article-title":"Differential mononuclear leukocyte attracting chemokine production after stimulation with active and inactivated influenza A virus","volume":"186","author":"Bussfeld","year":"1998","journal-title":"Cell Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2011.05.054_bib0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI1355","article-title":"Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defence","volume":"101","author":"Hayden","year":"1998","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2011.05.054_bib0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0887-8994(02)00452-6","article-title":"Possible contribution of interferon-alpha to febrile seizures in influenza","volume":"27","author":"Masuyama","year":"2002","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.1016\/j.vaccine.2011.05.054_bib0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/thx.2009.132480","article-title":"Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness","volume":"65","author":"Sumino","year":"2010","journal-title":"Thorax"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2011.05.054_bib0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jneuroim.2004.07.016","article-title":"Interferon-beta induces transient systemic IP-10\/CXCL10 chemokine release in patients with multiple sclerosis","volume":"156","author":"Buttmann","year":"2004","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.vaccine.2011.05.054_bib0095","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0168-8278(97)80269-3","article-title":"Seizures in children during interferon alpha therapy","volume":"26","author":"Woynarowski","year":"1997","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.05.054_bib0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0168-8278(96)80185-1","article-title":"Seizures during alpha interferon therapy","volume":"24","author":"Shakil","year":"1996","journal-title":"J Hepatol"},{"issue":"8730","key":"10.1016\/j.vaccine.2011.05.054_bib0105","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/0140-6736(90)93356-T","article-title":"Seizures associated with low-dose alpha-interferon","volume":"336","author":"Janssen","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2011.05.054_bib0110","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/JVI.01619-09","article-title":"Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons","volume":"84","author":"Osterlund","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.05.054_bib0115","doi-asserted-by":"crossref","unstructured":"Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Online, in press.","DOI":"10.1136\/bmjopen-2010-000016"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11007742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11007742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T07:54:59Z","timestamp":1543737299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11007742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":23,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0264410X11007742"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}